Rhythm Pharmaceuticals (RYTM) 주식 개요
상업화 단계의 바이오 제약 회사인 리듬 파마슈티컬스는 미국 및 국제적으로 희귀 신경내분비 질환에 초점을 맞추고 있습니다. 자세히 보기
강점
위험 분석
우리의 위험 점검에서 RYTM에 대한 위험이 감지되지 않았습니다.
RYTM Community Fair Values
Create NarrativeSee what 8 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Rhythm Pharmaceuticals, Inc. 경쟁사
가격 이력 및 성과
| 과거 주가 | |
|---|---|
| 현재 주가 | US$110.41 |
| 52주 최고가 | US$122.20 |
| 52주 최저가 | US$64.65 |
| 베타 | 1.92 |
| 1개월 변동 | 25.65% |
| 3개월 변동 | 27.95% |
| 1년 변동 | 64.99% |
| 3년 변동 | 589.63% |
| 5년 변동 | 462.74% |
| IPO 이후 변동 | 268.03% |
최근 뉴스 및 업데이트
내러티브 업데이트 • Jun 18
RYTM: PWS Phase 2 Progress Will Drive Next Phase Of Upside
Analysts have nudged their average price target on Rhythm Pharmaceuticals stock higher by about $1 to roughly $139, citing updated models that factor in recently reported interim Phase 2 data for setmelanotide in PWS, as well as a series of upward target revisions across the Street. Analyst Commentary Street research around Rhythm Pharmaceuticals centers on how the new Phase 2 setmelanotide data in PWS could affect valuation, execution risk, and the long term growth opportunity.내러티브 업데이트 • Jun 03
RYTM: Hypothalamic Obesity Approval Will Drive Next Phase Of Upside
Narrative Update The updated analyst price target framework for Rhythm Pharmaceuticals reflects a modest fair value move to $138.20, with analysts pointing to adjusted revenue growth expectations, higher projected profit margins, and a lower future P/E assumption after recent EMANATE trial readouts and reassessments of setmelanotide opportunities. Analyst Commentary Recent research updates on Rhythm Pharmaceuticals reflect a mix of optimism around near term commercial execution and concern around the implications of the EMANATE Phase 3 miss for longer term rare obesity opportunities.Recent updates
내러티브 업데이트 • Jun 18
RYTM: PWS Phase 2 Progress Will Drive Next Phase Of Upside
Analysts have nudged their average price target on Rhythm Pharmaceuticals stock higher by about $1 to roughly $139, citing updated models that factor in recently reported interim Phase 2 data for setmelanotide in PWS, as well as a series of upward target revisions across the Street. Analyst Commentary Street research around Rhythm Pharmaceuticals centers on how the new Phase 2 setmelanotide data in PWS could affect valuation, execution risk, and the long term growth opportunity.내러티브 업데이트 • Jun 03
RYTM: Hypothalamic Obesity Approval Will Drive Next Phase Of Upside
Narrative Update The updated analyst price target framework for Rhythm Pharmaceuticals reflects a modest fair value move to $138.20, with analysts pointing to adjusted revenue growth expectations, higher projected profit margins, and a lower future P/E assumption after recent EMANATE trial readouts and reassessments of setmelanotide opportunities. Analyst Commentary Recent research updates on Rhythm Pharmaceuticals reflect a mix of optimism around near term commercial execution and concern around the implications of the EMANATE Phase 3 miss for longer term rare obesity opportunities.Seeking Alpha • Jun 03
Rhythm Pharmaceuticals: The Rare Obesity Platform Is Becoming A Commercial Engine
Summary Rhythm Pharmaceuticals is transitioning from a development stage to a commercial rare disease leader, leveraging its IMCIVREE franchise for biologically defined obesity. IMCIVREE’s recent FDA and EU approvals for acquired hypothalamic obesity unlock a significant, underserved market with rapid early uptake and global expansion potential. RYTM’s premium valuation is justified by rapid revenue growth, multiple approved indications, global infrastructure, and a robust pipeline targeting rare neuroendocrine obesity. Key near-term catalysts include U.S. launch execution, Japanese regulatory decision, pivotal oral bivamelagon trial, and pipeline progress in congenital HO and PWS. Read the full article on Seeking Alpha내러티브 업데이트 • May 04
RYTM: Hypothalamic Obesity Expansion Will Drive Next Phase Of Upside
Rhythm Pharmaceuticals' consolidated analyst price target has been adjusted slightly higher by a few dollars to $137.67, as analysts update their models around recent EMANATE trial outcomes, hypothalamic obesity launch expectations, and evolving views on next generation MC4R agonist opportunities. Analyst Commentary Recent research updates show a mix of optimism and caution around Rhythm Pharmaceuticals, with several firms adjusting price targets both higher and lower as they factor in EMANATE outcomes, hypothalamic obesity indications, and next generation MC4R agonist programs.내러티브 업데이트 • Apr 19
RYTM: Hypothalamic Obesity Approval Will Drive Next Phase Of Upside
Analysts have nudged their blended price target for Rhythm Pharmaceuticals higher by $0.40 to $137.67, reflecting updated assumptions around revenue growth, profitability, discount rates, and future P/E multiples following recent research updates on Phase 3 trial outcomes and the commercial outlook for Imcivree and hypothalamic obesity. Analyst Commentary Recent research updates present a mixed but generally constructive picture, with several firms adjusting price targets following the EMANATE trial results and evolving expectations for Imcivree and hypothalamic obesity.내러티브 업데이트 • Apr 04
RYTM: Hypothalamic Obesity Expansion Will Drive Next Upside Phase
Rhythm Pharmaceuticals' fair value estimate has moved higher to $137.27 from $135.53, as analysts factor in recent price target revisions that balance EMANATE trial setbacks with continued focus on Imcivree commercial execution and next generation MC4R agonists. Analyst Commentary Street research around Rhythm Pharmaceuticals has shifted meaningfully following the EMANATE readout, with price targets adjusted both higher and lower as analysts weigh clinical risk against the commercial rollout of Imcivree and the potential of next generation MC4R agonists.내러티브 업데이트 • Mar 20
RYTM: Hypothalamic Obesity Approval And Launch Preparations Will Drive Next Upside Phase
The updated analyst model trims the blended price target for Rhythm Pharmaceuticals by about $4 to $135.53 as analysts factor in slightly lower revenue growth and margin assumptions, along with a higher projected future P/E multiple following recent EMANATE trial results and ongoing focus on Imcivree and hypothalamic obesity. Analyst Commentary Recent Street research around Rhythm Pharmaceuticals reflects a mixed but engaged view, with several firms adjusting price targets after EMANATE and other trial updates, as well as ongoing focus on Imcivree and hypothalamic obesity.내러티브 업데이트 • Mar 06
RYTM: Hypothalamic Obesity Launch And Upcoming Data Readouts Will Drive Next Upside Phase
Analysts trimmed their blended price target for Rhythm Pharmaceuticals by a few dollars, reflecting slightly more conservative long-term revenue and margin assumptions, even as they continue to highlight the potential of IMCIVREE and the hypothalamic obesity opportunity. Analyst Commentary Recent Street research around Rhythm Pharmaceuticals shows a mix of enthusiasm about the IMCIVREE franchise and the hypothalamic obesity opportunity, along with some recalibration of long-term expectations that feeds into updated price targets.내러티브 업데이트 • Feb 18
RYTM: Stable Franchise Trends Will Support Next Phase Of Upside
Analysts have lifted their price target on Rhythm Pharmaceuticals to $145 from $140, citing slightly stronger than expected preannounced Q4 Imcivree revenue of about $57M and what they see as stable growth trends for the existing franchise. Analyst Commentary Recent commentary centers on how the preannounced Q4 Imcivree revenue of about US$57M feeds into expectations for Rhythm Pharmaceuticals' execution and valuation.내러티브 업데이트 • Feb 04
RYTM: March Review Decision Will Drive Next Phase Of Upside
Analysts lifted their price target on Rhythm Pharmaceuticals to US$145 from US$140, citing Q4 Imcivree revenues of about US$57 million coming in slightly ahead of expectations and their view that growth in the existing franchise remains stable. Analyst Commentary Recent commentary around Rhythm Pharmaceuticals focuses on how the latest Imcivree revenue update might influence expectations for growth, execution, and valuation.내러티브 업데이트 • Jan 21
RYTM: March Hypothalamic Obesity Decision Will Drive Next Phase Of Upside
Narrative Update Overview Analysts have inched their fair value estimate for Rhythm Pharmaceuticals higher to about $140 from $139, reflecting slightly higher Street price targets and expectations for steady Imcivree demand after a Q4 revenue preannouncement of roughly $57 million. The update also takes into account more cautious views on how much near term upside is left around upcoming label and trial milestones.내러티브 업데이트 • Jan 06
RYTM: March Obesity Decision And Prader Willi Data Will Shape Upside
Analysts have nudged their fair value estimate for Rhythm Pharmaceuticals higher to about US$139 per share from roughly US$138, reflecting recent price target increases from several firms, along with views that upcoming label expansion and clinical readouts are already largely reflected in the current share price. Analyst Commentary Recent Street research on Rhythm Pharmaceuticals shows a mix of enthusiasm around the commercial trajectory and upcoming label events, alongside some caution on how much of that story is already reflected in the share price.내러티브 업데이트 • Dec 21
RYTM: March FDA Obesity Decision Will Drive Next Phase Of Upside
Analysts have modestly lifted their fair value estimate for Rhythm Pharmaceuticals to approximately $138 from about $127, reflecting slightly higher long term revenue growth expectations and confidence in upcoming hypothalamic obesity label expansion, despite a recent downgrade on valuation concerns. Analyst Commentary Bullish analysts highlight that Rhythm's strong clinical execution in hypothalamic obesity and Bardet Biedl syndrome, along with robust year to date share performance, support a higher long term revenue trajectory and justify incremental price target increases.내러티브 업데이트 • Dec 07
RYTM: March FDA Obesity Decision Will Drive Next Phase Of Share Upside
Analysts have edged their average price target for Rhythm Pharmaceuticals slightly higher to about $127 from roughly $126, reflecting confidence that strong Imcivree and bivamelagon data, along with anticipated hypothalamic obesity label expansion, can support continued growth. However, recent gains and a limited near term catalyst slate are tempering enthusiasm.내러티브 업데이트 • Nov 23
RYTM: December FDA Decision Will Drive Next Phase Of Share Upside
Rhythm Pharmaceuticals' analyst price target increased from $121.43 to $126.31, as analysts cite ongoing clinical progress and upcoming regulatory milestones that support further upside for the company’s shares. Analyst Commentary Analysts have recently weighed in on Rhythm Pharmaceuticals, offering both optimistic and cautionary perspectives based on the company's performance, upcoming catalysts, and valuation.분석 기사 • Nov 07
The Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Third-Quarter Results Are Out And Analysts Have Published New Forecasts
It's been a sad week for Rhythm Pharmaceuticals, Inc. ( NASDAQ:RYTM ), who've watched their investment drop 12% to...내러티브 업데이트 • Nov 05
RYTM: Upcoming FDA Decision Will Drive Next Phase of Upside Momentum
Analysts have raised their price target for Rhythm Pharmaceuticals from $117.57 to $121.43 per share, citing improved profit margin projections and increased optimism about upcoming label expansions for setmelanotide. Analyst Commentary Recent updates from Street research provide a balanced view on Rhythm Pharmaceuticals, with both bullish and bearish perspectives influencing the company's outlook and valuation.내러티브 업데이트 • Oct 22
Analysts Boost Rhythm Pharmaceuticals Outlook Amid Setmelanotide Progress and Revised Valuation Metrics
The analyst price target for Rhythm Pharmaceuticals was revised upward by $7 to reflect increased optimism from analysts about the company's potential label expansion and expected regulatory progress for setmelanotide in hypothalamic obesity. Analyst Commentary Recent updates from Street research indicate a positive reassessment of Rhythm Pharmaceuticals' prospects, particularly surrounding potential regulatory approval and expanding commercial opportunities for setmelanotide in hypothalamic obesity.내러티브 업데이트 • Oct 08
Rising Genetic Diagnosis Will Expand Rare Disease Treatment Pipelines
Rhythm Pharmaceuticals' analyst price target has increased from $114.86 to $118.36, as analysts cite encouraging clinical data and optimism about setmelanotide's approval prospects in hypothalamic obesity. These factors are driving the revised valuation.내러티브 업데이트 • Sep 24
Rising Genetic Diagnosis Will Expand Rare Disease Treatment Pipelines
The consensus price target for Rhythm Pharmaceuticals was raised to $114.86 as bullish analyst sentiment strengthened on strong Phase 2 obesity trial results, robust Imcivree sales, and optimistic expectations for regulatory milestones and long-term franchise durability. Analyst Commentary Bullish analysts highlight strong Phase 2 trial results for bivamelagon in hypothalamic obesity, demonstrating significant placebo-adjusted BMI reduction at multiple doses and exceeding expectations for efficacy over 14 weeks.내러티브 업데이트 • Aug 07
Rising Genetic Diagnosis Will Expand Rare Disease Treatment Pipelines
A lower future P/E indicates improved earnings expectations, while a higher discount rate suggests increased perceived risk, yet analysts have still raised Rhythm Pharmaceuticals’ fair value to $110.71 per share. What's in the News Rhythm Pharmaceuticals presented new clinical data on bivamelagon (oral MC4R agonist) and setmelanotide (lead asset) in patients with acquired hypothalamic obesity at ENDO 2025; setmelanotide remains FDA approved for syndromic monogenic obesity due to defined genetic deficiencies.분석 기사 • Jul 10
Revenues Not Telling The Story For Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) After Shares Rise 33%
Rhythm Pharmaceuticals, Inc. ( NASDAQ:RYTM ) shares have continued their recent momentum with a 33% gain in the last...새로운 내러티브 • May 26
Label Expansion And Global Healthcare Will Widen Future Market Opportunities
Label expansion and global commercialization of IMCIVREE are set to drive substantial revenue growth and broaden market reach.Seeking Alpha • Apr 08
Rhythm: Late-Stage Study Win Brings About Change For Rare Obesity Disorder
Summary Rhythm Pharmaceuticals, Inc. met primary endpoint in phase 3 TRANSCEND study, which used setmelanotide for the treatment of patients with acquired hypothalamic obesity. Regulatory submission of setmelanotide to the U.S. and EU, for the treatment of patients with acquired hypothalamic obesity, expected in Q3 of 2025. Company pushing forward with oral MC4R-specific agonist to treat patients with acquired hypothalamic obesity known as bivamelagon; Data from a phase 1/2 study, using bivamelagon for the treatment of patients with acquired hypothalamic obesity, expected in 2nd half of 2025. Read the full article on Seeking AlphaSeeking Alpha • Feb 25
Rhythm Pharmaceuticals: Buying This Rare Genetic Obesity Maven
Summary Rhythm Pharmaceuticals' 01/2025 presentation and Q4 2024 preliminary results press release highlight growing financial performance and promising pipeline developments. Investment thesis focuses on Rhythm's robust clinical progress and strategic positioning in the rare genetic obesity market. Rating justification is based on solid revenues, innovative product pipeline, and potential market expansion. Conclusion emphasizes Rhythm's growth potential and recommends it as a compelling speculative investment opportunity. Read the full article on Seeking AlphaSeeking Alpha • Dec 06
Rhythm Pharmaceuticals: A Key Year Ahead
Summary Rhythm Pharmaceuticals, Inc.'s main asset, imcivree, targets rare genetic obesity disorders; key milestones in 2025 could significantly impact the stock. Positive Phase 3 data and expanded indications for imcivree, including Hypothalamic Obesity, are crucial for future growth. Analysts are optimistic, with multiple Buy ratings and price targets between $65-$80; however, insiders have sold some shares recently. An updated analysis around Rhythm Pharmaceuticals follows in the paragraphs below. Read the full article on Seeking AlphaSeeking Alpha • Sep 22
Rhythm: Upcoming sNDA Label Expansion IMCIVREE Isn't The Only Catalyst On Deck
Summary IMCIVREE is FDA-approved for obesity due to genetic mutations and aims to expand its label to include children as young as 2 years old. Rhythm is also exploring IMCIVREE for hypothalamic obesity in a phase 3 study, with data expected in the 1st half of 2025. Financially, Rhythm has $319.1 million in cash, but may need to raise more funds within the next 12 months. RM-718 and LB54640 are two other drugs being developed to treat patients with hypothalamic obesity; Both of which are able to achieve function without hyperpigmentation. Read the full article on Seeking AlphaSeeking Alpha • Aug 29
Rhythm: Pivotal Moment Approaching In Hypothalamic Obesity (Rating Upgrade)
Summary Rhythm Pharmaceuticals' Q2 revenue rose to $29.1 million, driven by global sales of Imcivree, its treatment for rare genetic obesity disorders. The company's cash and investments totaled $319 million by June 30, 2024, ensuring a cash runway into 2026, according to Rhythm's projections. Imcivree is currently undergoing a Phase 3 trial for hypothalamic obesity, with results expected in 1H 2025, crucial for its potential blockbuster status. RYTM stock is a speculative "buy" based on the potential of Imcivree in treating hypothalamic obesity, though there are significant risks if the trial fails. Read the full article on Seeking AlphaSeeking Alpha • Jun 12
Rhythm: Navigating Imcivree's Potential In Rare Obesity Treatments (Rating Upgrade)
Summary Rhythm Pharmaceuticals' stock has appreciated 68% since the last sell recommendation, outperforming market returns. Imcivree shows promising Phase 2 results in treating hypothalamic obesity, potentially doubling its market if its Phase 3 trial proves successful. The company's financial health appears stable, with a sufficient cash runway extended by recent funding. The Phase 3 trial for Imcivree in heterozygous mutations aims to broaden the addressable population to exceed 50,000. I now hold a more balanced view of RYTM stock, acknowledging its strategic expansions but cautious of its high valuation and ongoing risks. Read the full article on Seeking AlphaSeeking Alpha • Feb 23
Rhythm Pharmaceuticals: Action Too Specific
Summary Rhythm Pharmaceuticals focuses on treating obesity caused by genetic mutations, but the market size for these mutations is too small to justify the company's valuation. Novo Nordisk's Ozempic also targets the same patient groups, making Rhythm's product less appealing. IMCIVREE, Rhythm's main product, shows good results in clinical trials, but again the action is too specific. Outstanding dilution from options too down the line. Not for us. Read the full article on Seeking Alpha주주 수익률
| RYTM | US Biotechs | US 시장 | |
|---|---|---|---|
| 7D | 2.7% | 3.7% | 1.6% |
| 1Y | 65.0% | 37.9% | 21.1% |
수익률 대 산업: RYTM은 지난 1년 동안 37.9%의 수익을 기록한 US Biotechs 산업보다 더 좋은 성과를 냈습니다.
수익률 대 시장: RYTM은 지난 1년 동안 21.1%를 기록한 US 시장보다 더 좋은 성과를 냈습니다.
주가 변동성
| RYTM volatility | |
|---|---|
| RYTM Average Weekly Movement | 6.1% |
| Biotechs Industry Average Movement | 10.3% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.1% |
안정적인 주가: RYTM는 지난 3개월 동안 US 시장에 비해 주가 변동성이 크지 않았습니다.
시간에 따른 변동성: RYTM의 주간 변동성(6%)은 지난 1년 동안 안정적이었습니다.
회사 소개
| 설립 | 직원 수 | CEO | 웹사이트 |
|---|---|---|---|
| 2008 | 414 | David Meeker | rhythmtx.com |
상업화 단계의 바이오 제약 회사인 리듬 파마슈티컬스는 미국 및 국제적으로 희귀 신경내분비 질환에 초점을 맞추고 있습니다. 이 회사의 주요 제품 후보는 프로오피오멜라노코르틴(POMC), 프로프로틴 전환효소 서브틸리신/켁신 1형, 렙틴 수용체(LEPR) 결핍 비만, 바르데-비들 및 알스트롬 증후군, 프라더-윌리 증후군, 시상하부 비만 치료를 위한 희귀 멜라노코르틴-4 수용체 임씨브리(세트멜라노타이드)입니다. 후천성 시상하부 비만, 선천성 시상하부 비만, 프로오피오멜라노코르틴(POMC) 및 LEPR 결핍 비만, SRC1 결핍 비만, SH2B1 결핍 비만 치료를 위한 3상 임상시험과 프라더-윌리 증후군 및 MC4R 결핍 치료를 위한 2상 임상시험을 진행 중입니다.
Rhythm Pharmaceuticals, Inc. 기초 지표 요약
| RYTM 기초 통계 | |
|---|---|
| 시가총액 | US$7.61b |
| 순이익 (TTM) | -US$207.84m |
| 매출 (TTM) | US$217.17m |
34.8x
주가매출비율(P/S)-36.4x
주가수익비율(P/E)RYTM는 고평가되어 있습니까?
공정 가치 및 평가 분석 보기순이익 및 매출
| RYTM 손익계산서 (TTM) | |
|---|---|
| 매출 | US$217.17m |
| 매출원가 | US$23.00m |
| 총이익 | US$194.16m |
| 기타 비용 | US$402.00m |
| 순이익 | -US$207.84m |
최근 보고된 실적
Mar 31, 2026
다음 실적 발표일
해당 없음
| 주당순이익(EPS) | -3.03 |
| 총이익률 | 89.41% |
| 순이익률 | -95.71% |
| 부채/자본 비율 | 45.6% |
RYTM의 장기 실적은 어땠습니까?
과거 실적 및 비교 보기기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/07/01 19:20 |
| 종가 | 2026/07/01 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Rhythm Pharmaceuticals, Inc.는 25명의 분석가가 다루고 있습니다. 이 중 16명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Tazeen Ahmad | BofA Global Research |
| Whitney Ijem | Canaccord Genuity |
| Samantha Lynn Semenkow | Citigroup Inc |